Figure 5
Figure 5. Effect of ERK-dependent suppression of hnRNP-E2 on C/EBPα expression and neutrophilic differentiation of Lin− BMC-BCR/ABLhigh cells and patient-derived CML-BCCD34+ progenitors. (A) Levels of hnRNP-E2, C/EBPα, G-CSFR, phospho-ERK1/2, and total ERK1/2 in lineage-negative (Lin−) mouse bone marrow cells (BMCs) transduced with the empty vector (Lin−BMC-MigRI) or with a p210-BCR/ABL retrovirus and sorted for low and high GFP expression (Lin−BMC-BCR/ABLlow and -BCR/ABLhigh) (left panel). Effect of MAPK inhibition by U0126 on hnRNP-E2 and C/EBPα expression and/or G-CSF–driven differentiation in Lin− BMC-BCR/ABLhigh cells (middle and right panels). May-Grumwald/Giemsa–stained representative microphotographs of Lin− BMC-MigRI, BMC-BCR/ABLlow, untreated, and U0126-treated BMC-BCR/ABLhigh cells (right panel). (B) Effect of MAPK inhibition by U0126 and CI-1040 on hnRNP-E2 and C/EBPα expression in primary CD34+ human normal bone marrow cells (NBMCD34+) and CML-BCCD34+ cells (left panel). May-Grumwald/Giemsa staining of NBMCD34+ and untreated, U0126-treated, and CI-1040-treated CML-BCCD34+ cells (right panel).

Effect of ERK-dependent suppression of hnRNP-E2 on C/EBPα expression and neutrophilic differentiation of Lin BMC-BCR/ABLhigh cells and patient-derived CML-BCCD34+ progenitors. (A) Levels of hnRNP-E2, C/EBPα, G-CSFR, phospho-ERK1/2, and total ERK1/2 in lineage-negative (Lin) mouse bone marrow cells (BMCs) transduced with the empty vector (LinBMC-MigRI) or with a p210-BCR/ABL retrovirus and sorted for low and high GFP expression (LinBMC-BCR/ABLlow and -BCR/ABLhigh) (left panel). Effect of MAPK inhibition by U0126 on hnRNP-E2 and C/EBPα expression and/or G-CSF–driven differentiation in Lin BMC-BCR/ABLhigh cells (middle and right panels). May-Grumwald/Giemsa–stained representative microphotographs of Lin BMC-MigRI, BMC-BCR/ABLlow, untreated, and U0126-treated BMC-BCR/ABLhigh cells (right panel). (B) Effect of MAPK inhibition by U0126 and CI-1040 on hnRNP-E2 and C/EBPα expression in primary CD34+ human normal bone marrow cells (NBMCD34+) and CML-BCCD34+ cells (left panel). May-Grumwald/Giemsa staining of NBMCD34+ and untreated, U0126-treated, and CI-1040-treated CML-BCCD34+ cells (right panel).

Close Modal

or Create an Account

Close Modal
Close Modal